CTOs on the Move

Sparklight

www.sparklight.com

 
Sparklight, a DBA of Cable ONE, Inc. (NYSE: CABO) is a leading broadband communications provider serving more than 800,000 residential and business customers in 21 states. Sparklight provides consumers with a wide array of connectivity and entertainment services, including high-speed internet and advanced Wi-Fi solutions, cable television and phone service. Sparklight Business provides scalable and cost-effective products for businesses ranging in size from small to mid-market, in addition to enterprise, wholesale and carrier customers. Sparklight Advertising provides digital marketing, video production, website development and hosting, and cable television advertising services to businesses across the US. Sparklight, connecting you to what ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Dale Stanley
Senior Director, Information Technology Profile
Kenneth Johnson
Senior Vice President of Technology Services Profile

Similar Companies

Vertical Relevance

Your trusted industry partner in Business Transformation, Customer Experience, & Cloud Services.

ELSA Speak

Our speech recognition app is designed to evaluate and give feedback on your English pronunciation and fluency. With ELSA you can speak English like a natural.

Advent eModal

Advent provides innovative, cloud-based software for shippers, terminal operators & truckers seeking to improve productivity & operational efficiencies.

South Division Credit Union

South Division Credit Union is dedicated to providing quality financial products and services that exceed the needs of our members and their families.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.